Internet Archive Scholar

Editor's Note: Cotreatment with STI-571 Enhances Tumor Necrosis Factor α-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)–induced Apoptosis of Bcr-Abl–positive Human Acute Leukemia Cells

Ramadevi Nimmanapalli, Mercedes Porosnicu, Diep Nguyen, Elizabeth Worthington, Erica O'Bryan, Charles Perkins, Kapil Bhalla
2019 Clinical Cancer Research  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (149.5 kB)
https://web.archive.org/web/20200305193931/https://clincancerres.aacrjournals.org/content/clincanres/25/13/4195.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

et al. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
doi:10.1158/1078-0432.ccr-19-1602 fatcat:hwzolxhpvbdspkjrbjwocphnte
Citation

Ramadevi Nimmanapalli, Mercedes Porosnicu, Diep Nguyen, Elizabeth Worthington, Erica O'Bryan, Charles Perkins, Kapil Bhalla. "Editor's Note: Cotreatment with STI-571 Enhances Tumor Necrosis Factor α-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)–induced Apoptosis of Bcr-Abl–positive Human Acute Leukemia Cells." Clinical Cancer Research 25.13 (2019) 4195-4195